Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced its participation in the 6th Macrophage-Directed Therapies Summit in Boston, MA, from October 1-3, 2024. The company will present its work on the proprietary Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to program innate immune cells to combat specific cancers and viral threats.
The presentation will focus on using the CBR platform for treating rare cancers. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in myeloid cell therapies and engage with potential collaborators and investors. This event highlights Hemogenyx's commitment to developing innovative treatments for life-threatening diseases, showcasing its state-of-the-art research capabilities in New York City.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha annunciato la sua partecipazione al 6° Summit sulle Terapie Dirette ai Macrofagi a Boston, MA, dal 1 al 3 ottobre 2024. L'azienda presenterà il proprio lavoro sulla piattaforma proprietaria Chimeric Bait Receptor (CBR), una immunoterapia avanzata progettata per programmare le cellule immunitarie innate per combattere canceri specifici e minacce virali.
La presentazione si concentrerà sull'utilizzo della piattaforma CBR per il trattamento di cancro rari. Il Dr. Vladislav Sandler, CEO e Co-Fondatore, ha sottolineato l'opportunità di stabilire la posizione di Hemogenyx nelle terapie cellulari mieloidi e di coinvolgere potenziali collaboratori e investitori. Questo evento evidenzia l'impegno di Hemogenyx nello sviluppo di trattamenti innovativi per malattie potenzialmente letali, mostrando le sue capacità di ricerca all'avanguardia nella città di New York.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha anunciado su participación en el 6º Cumbre de Terapias Dirigidas a Macrófagos en Boston, MA, del 1 al 3 de octubre de 2024. La empresa presentará su trabajo sobre la plataforma propietaria Receptor Cebador Quimérico (CBR), una inmunoterapia avanzada diseñada para programar las células inmunitarias innatas para combatir ciertos cánceres y amenazas virales.
La presentación se centrará en el uso de la plataforma CBR para tratar cánceres raros. El Dr. Vladislav Sandler, CEO y cofundador, enfatizó la oportunidad de establecer la posición de Hemogenyx en terapias de células mieloides y de involucrar a posibles colaboradores e inversores. Este evento destaca el compromiso de Hemogenyx con el desarrollo de tratamientos innovadores para enfermedades potencialmente mortales, mostrando sus capacidades de investigación de vanguardia en la ciudad de Nueva York.
헤모제닉스 제약 (LSE:HEMO)는 2024년 10월 1일부터 3일까지 매사추세츠주 보스턴에서 열리는 제6회 대식세포 지향 치료법 정상 회담에 참가한다고 발표했습니다. 이 회사는 특정 암과 바이러스 위협에 맞서 싸우기 위해 선천적인 면역 세포를 프로그래밍하도록 설계된 고급 면역 요법인 독점 키메라 미끼 수용체(CBR) 플랫폼에 대한 작업을 발표할 예정입니다.
발표는 CBR 플랫폼을 사용하여 희귀 암 치료에 중점을 둘 것입니다. 블라디슬라프 샌들러 박사, CEO 겸 공동 창립자는 헤모제닉스의 골수 세포 치료 분야에서의 입지를 확립하고 잠재적인 협력자 및 투자자와의 참여 기회를 강조했습니다. 이 행사는 생명을 위협하는 질병에 대한 혁신적인 치료법 개발에 대한 헤모제닉스의 의지를 강조하며, 뉴욕에서의 최첨단 연구 능력을 보여줍니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a annoncé sa participation au 6ème Sommet sur les Thérapies Dirigées par les Macrophages à Boston, MA, du 1er au 3 octobre 2024. L'entreprise présentera ses travaux sur la plateforme propriétaire Chimeric Bait Receptor (CBR), une immunothérapie avancée conçue pour programmer les cellules immunitaires innées afin de lutter contre des cancers spécifiques et des menaces virales.
La présentation se concentrera sur l'utilisation de la plateforme CBR pour le traitement de cancers rares. Dr. Vladislav Sandler, PDG et co-fondateur, a souligné l'opportunité d'établir la position de Hemogenyx dans les thérapies cellulaires myéloïdes et d'engager des collaborations potentielles avec des investisseurs. Cet événement met en lumière l'engagement de Hemogenyx à développer des traitements innovants pour les maladies menaçantes pour la vie, et met en avant ses capacités de recherche de pointe à New York.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat seine Teilnahme am 6. Gipfel zu Makrophagengelenkten Therapien in Boston, MA, vom 1. bis 3. Oktober 2024 bekannt gegeben. Das Unternehmen wird seine Arbeiten zur proprietären Chimeric Bait Receptor (CBR)-Plattform präsentieren, einer fortschrittlichen Immuntherapie, die darauf abzielt, angeborene Immunzellen zu programmieren, um spezifische Krebsarten und virale Bedrohungen zu bekämpfen.
Die Präsentation wird sich auf die Nutzung der CBR-Plattform zur Behandlung von seltenen Krebserkrankungen konzentrieren. Dr. Vladislav Sandler, CEO und Mitgründer, betonte die Möglichkeit, Hemogenyx' Position im myeloiden Zelltherapie-Bereich zu etablieren und potenzielle Kooperationspartner und Investoren anzusprechen. Diese Veranstaltung hebt das Engagement von Hemogenyx hervor, innovative Behandlungen für lebensbedrohliche Krankheiten zu entwickeln, und zeigt die hochmodernen Forschungskapazitäten in New York City.
- None.
- None.
Presentation at Macrophage-Directed Therapies Summit
LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 6th Macrophage-Directed Therapies Summit ("Summit"), which will be held on October 1-3, 2024, in Boston, MA. The Company will present its work on its proprietary Chimeric Bait Receptor ("CBR") platform.
The Company's CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer as well as combat infections from both existing and emerging viral threats. The Company's presentation at the Summit will focus on the use of the CBR platform for the treatment of rare cancers.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the Summit will provide the Company with an opportunity to further establish its unique position in the emerging field of myeloid cell therapies. It will also allow us to exchange ideas with like-minded cell therapy developers, potential collaborators, and investors."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What event is Hemogenyx Pharmaceuticals (HOPHF) participating in on October 1-3, 2024?
What will Hemogenyx Pharmaceuticals present at the Macrophage-Directed Therapies Summit?
What is the Chimeric Bait Receptor (CBR) platform developed by Hemogenyx Pharmaceuticals?
Where are Hemogenyx Pharmaceuticals' US operating subsidiaries located?
